Advertisement

Drug Safety

, Volume 29, Issue 8, pp 647–656 | Cite as

Long-Acting β2-Agonists in Asthma

Not so SMART?
  • Graeme P. Currie
  • Daniel K.C. Lee
  • Brian J. Lipworth
Current Opinion

Abstract

Asthma is a worldwide chronic disorder that is characterised by airway inflammation and hyper-responsiveness, which results in intermittent airflow obstruction and subsequent perception of symptoms and exacerbations. Inhaled corticosteroids are a fundamental component in the prevention of the short- and long-term complications associated with inadequately controlled asthma. However, many individuals experience persistent symptoms and exacerbations despite receiving low-to-medium doses of an inhaled corticosteroid (400–800 μg/day of beclometasone or equivalent). In these symptomatic asthmatic patients, guidelines advocate the initiation of a long-acting β2-adrenoceptor agonist (LABA) as additional second-line controller therapy.

The recent SMART (Salmeterol Multi-centre Asthma Research Trial) study was designed to compare the effects of add-on salmeterol 42 μg (ex-actuator) twice daily with placebo over 28 weeks in a randomised, double-blind, parallel-group fashion, with the intention to enrol 60 000 asthmatic patients. However, the study was halted prematurely because preliminary data revealed an increased mortality associated with regular use of salmeterol. Moreover, concerning rates of respiratory-related deaths, asthma-related deaths and life-threatening events were observed among African Americans, who constituted up to 18% of the study population. This in turn prompted the US FDA to announce important safety information regarding inhalers containing LABAs and advise that new labelling be produced outlining the “ small but significant risk in asthma-related deaths” associated with their regular use. This evidence-based review discusses the data from SMART and highlights potentially important drawbacks with regular use of LABAs in persistent asthma.

Keywords

Budesonide Fluticasone Propionate Salmeterol Formoterol Persistent Asthma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Graeme P. Currie has received funding from GlaxoSmithKline (who make salmeterol), AstraZeneca (who make formoterol) and Merck & Co. (who make montelukast) for attending postgraduate educational international meetings and honoraria for giving talks. Brian J. Lipworth has received funding for consulting activity from AstraZeneca and grant support from GlaxoSmithKline for a local postgraduate educational activity. Brian J. Lipworth has also received financial support from Merck & Co. for clinical trials and giving postgraduate educational talks. Daniel K.C. Lee has no conflicts of interest that are directly relevant to the content of this review. No sources of funding were used in the preparation of this article.

References

  1. 1.
    Currie GP, Lee DK, Wilson AM. Effects of dual therapy with corticosteroids plus long acting beta(2)-agonists in asthma. Respir Med 2005; 99: 683–94PubMedCrossRefGoogle Scholar
  2. 2.
    GINA Workshop Report, Global Strategy for Asthma Management and Prevention - updated 2004. Scientific information and recommendations for asthma programs. NIH Publication No. 02-3659Google Scholar
  3. 3.
    British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58 Suppl. 1: i1–94Google Scholar
  4. 4.
    Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26PubMedCrossRefGoogle Scholar
  5. 5.
    SLGA5011: a double-blind, randomized, placebo-controlled surveillance study of asthma event outcomes in subjects receiving either usual pharmacotherapy of asthma or usual pharmacotherapy plus salmeterol 42μg twice daily [online]. Available from URL: http://www.ctr.gsk.co.uk/Summary/salmeterol/studylist.asp [Accessed 2005 Dec 7]Google Scholar
  6. 6.
    Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124: 70–4PubMedCrossRefGoogle Scholar
  7. 7.
    Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists: is there cause for concern? Drug Saf 1997; 16: 295–308PubMedCrossRefGoogle Scholar
  8. 8.
    Lipworth B, Tan S, Devlin M, et al. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998; 104: 431–8PubMedCrossRefGoogle Scholar
  9. 9.
    Aziz I, Tan KS, Hall IP, et al. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur Respir J 1998; 12: 580–4PubMedCrossRefGoogle Scholar
  10. 10.
    Kalra S, Swystun VA, Bhagat R, et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953–6PubMedCrossRefGoogle Scholar
  11. 11.
    Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201–6PubMedCrossRefGoogle Scholar
  12. 12.
    Currie GP, Jackson CM, Ogston SA, et al. Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids. Q J Med 2003; 96: 435–40CrossRefGoogle Scholar
  13. 13.
    Green SA, Turki J, Bejarano P, et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13: 25–33PubMedGoogle Scholar
  14. 14.
    Tan S, Hall IP, Dewar J, et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350: 995–9PubMedCrossRefGoogle Scholar
  15. 15.
    Lipworth BJ, Dempsey OJ, Aziz I. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. Chest 2000; 118: 321–8PubMedCrossRefGoogle Scholar
  16. 16.
    Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173: 519–26PubMedCrossRefGoogle Scholar
  17. 17.
    Lee DK, Currie GP, Hall IP, et al. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004; 57: 68–75PubMedCrossRefGoogle Scholar
  18. 18.
    Xie HG, Stein CM, Kim RB, et al. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 1999; 9: 511–6PubMedGoogle Scholar
  19. 19.
    McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924–30PubMedGoogle Scholar
  20. 20.
    Nials AT, Ball DI, Butchers PR, et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994; 251: 127–35PubMedCrossRefGoogle Scholar
  21. 21.
    Chong LK, Cooper E, Vardey CJ, et al. Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms. Br J Pharmacol 1998; 123: 1009–15PubMedCrossRefGoogle Scholar
  22. 22.
    Erjefalt I, Persson CG. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. Am Rev Respir Dis 1991; 144: 788–91PubMedCrossRefGoogle Scholar
  23. 23.
    Bolton PB, Lefevre P, McDonald DM. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997; 155: 1428–35PubMedGoogle Scholar
  24. 24.
    Verleden GM, Belvisi MG, Rabe KF, et al. Beta 2-adrenoceptor agonists inhibit NANC neural bronchoconstrictor responses in vitro. J Appl Physiol 1993; 74: 1195–9PubMedCrossRefGoogle Scholar
  25. 25.
    Calhoun WJ, Hinton KL, Kratzenberg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med 2001; 163: 881–6PubMedGoogle Scholar
  26. 26.
    Gardiner PV, Ward C, Booth H, et al. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150: 1006–11PubMedGoogle Scholar
  27. 27.
    Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285: 2583–93PubMedCrossRefGoogle Scholar
  28. 28.
    Wallin A, Sue-Chu M, Bjermer L, et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol 2003; 112: 72–8PubMedCrossRefGoogle Scholar
  29. 29.
    Li X, Ward C, Thien F, et al. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493–9PubMedGoogle Scholar
  30. 30.
    Wallin A, Sandstrom T, Soderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159: 79–86PubMedGoogle Scholar
  31. 31.
    Lemanske RF, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285: 2594–603PubMedCrossRefGoogle Scholar
  32. 32.
    Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293–9PubMedCrossRefGoogle Scholar
  33. 33.
    Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274: 1005–10PubMedCrossRefGoogle Scholar
  34. 34.
    Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172: 704–12PubMedCrossRefGoogle Scholar
  35. 35.
    Orsida BE, Ward C, Li X, et al. Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001; 164: 117–21PubMedGoogle Scholar
  36. 36.
    Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J Allergy Clin Immunol 2002; 110: S261–8PubMedCrossRefGoogle Scholar
  37. 37.
    Mak JC, Hisada T, Salmon M, et al. Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol 2002; 135: 987–96PubMedCrossRefGoogle Scholar
  38. 38.
    Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105: 1108–16PubMedCrossRefGoogle Scholar
  39. 39.
    Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527–34PubMedGoogle Scholar
  40. 40.
    Currie GP, Bates CE, Lee DK, et al. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol 2003; 59: 11–5PubMedGoogle Scholar
  41. 41.
    Currie GP, Lee DK, Haggart K, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003; 167: 1232–8PubMedCrossRefGoogle Scholar
  42. 42.
    Aziz I, Wilson AM, Lipworth BJ. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 2000; 118: 1049–58PubMedCrossRefGoogle Scholar
  43. 43.
    Lee DK, Jackson CM, Currie GP, et al. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin Pharmacol 2003; 56: 494–500PubMedCrossRefGoogle Scholar
  44. 44.
    Lee DK, Jackson CM, Bates CE, et al. Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Thorax 2004; 59: 662–7PubMedCrossRefGoogle Scholar
  45. 45.
    van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. Thorax 2001; 56: 529–35PubMedCrossRefGoogle Scholar
  46. 46.
    van Veen A, Weller FR, Wierenga EA, et al. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther 2003; 16: 153–61PubMedCrossRefGoogle Scholar
  47. 47.
    Fuglsang G, Vikre-Jorgensen J, Agertoft L, et al. Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. Pediatr Pulmonol 1998; 25: 314–21PubMedCrossRefGoogle Scholar
  48. 48.
    Lipworth BJ, Aziz I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immunol 1999; 103: 88–92PubMedCrossRefGoogle Scholar
  49. 49.
    Jones SL, Cowan JO, Flannery EM, et al. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J 2001; 17: 368–73PubMedCrossRefGoogle Scholar
  50. 50.
    Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836–44PubMedCrossRefGoogle Scholar
  51. 51.
    Currie GP, Lee DK. The GOAL study: designed to favor a long-acting beta2-agonist? Am J Respir Crit Care Med 2005; 171: 1060–1PubMedGoogle Scholar
  52. 52.
    Fardon TC, Lipworth BJ. An own GOAL or a real breakthrough? Am J Respir Crit Care Med 2005; 171: 1060PubMedGoogle Scholar
  53. 53.
    Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368–73PubMedCrossRefGoogle Scholar
  54. 54.
    Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005; 60: 730–4PubMedCrossRefGoogle Scholar
  55. 55.
    Barnes ML, Lipworth BJ. Clinical importance of the Step 3 choice in asthma. Thorax 2006; 61: 180–1PubMedCrossRefGoogle Scholar
  56. 56.
    Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405–11PubMedCrossRefGoogle Scholar
  57. 57.
    Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57: 309–16PubMedCrossRefGoogle Scholar
  58. 58.
    Reddel HK, Jenkins CR, Marks GB, et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000; 16: 226–35PubMedCrossRefGoogle Scholar
  59. 59.
    Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: 941–55PubMedCrossRefGoogle Scholar
  60. 60.
    Bousquet J, Jeffery PK, Busse WW, et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720–45PubMedGoogle Scholar
  61. 61.
    Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001; 323: 253–6PubMedCrossRefGoogle Scholar
  62. 62.
    Currie GP, Fowler SJ, Lipworth BJ. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann Allergy Asthma Immunol 2003; 90: 194–8PubMedCrossRefGoogle Scholar
  63. 63.
    Lurie P, Wolfe SM. Misleading data analyses in salmeterol (SMART) study. Lancet 2005; 366: 1261–2PubMedCrossRefGoogle Scholar
  64. 64.
    O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392–7PubMedGoogle Scholar
  65. 65.
    Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071–6PubMedCrossRefGoogle Scholar
  66. 66.
    Currie GP, Lee DK, Srivastava P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest 2005; 128: 2954–62PubMedCrossRefGoogle Scholar
  67. 67.
    Martinez FD. Safety of long-acting beta-agonists: an urgent need to clear the air. N Engl J Med 2005; 353: 2637–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Graeme P. Currie
    • 1
  • Daniel K.C. Lee
    • 2
  • Brian J. Lipworth
    • 3
  1. 1.Department of Respiratory Medicine, graeme.currie@nhs.netAberdeen Royal InfirmaryForesterhill, AberdeenUK
  2. 2.Department of Respiratory MedicinePapworth HospitalPapworth EverardUK
  3. 3.Division of Medicine & Therapeutics, Asthma & Allergy Research GroupNinewells Hospital & Perth Royal InfirmaryDundeeUK

Personalised recommendations